Article

OBJECTIVE: To report outcomes regarding general and specific physical
health-related quality of life of treatment with percutaneous osseointegrated
prostheses. DESIGN: Prospective 2-year case-control study. SETTING: University
hospital. PARTICIPANTS: Individuals (N=39; mean age,
44 +/- 12.4 y) with
unilateral transfemoral amputation as a result of trauma (n=23), tumor (n=11), or
other cause (n=5). At baseline, 33 of the 39 participants used socket-suspended
prostheses. INTERVENTION: Osseointegrated prosthesis. MAIN OUTCOME MEASURES:
Questionnaire for Persons with Transfemoral Amputation (Q-TFA), Medical Outcomes
Study 36-Item Short-Form Health Survey (SF-36) physical functioning (PF) and
physical component summary (PCS), SF-6D, and Physiological Cost Index (PCI).
RESULTS: At 2 years postimplantation, 6 of 7 Q-TFA scores improved (P<.0001)
compared with baseline (prosthetic use, mobility, problem, global, capability,
walking habits). The walking aid subscore did not improve (P=.327). Of the 39
participants, increased prosthesis use was reported by 26, same amount of use by
11, and less use by 2. Improvement was reported in 16 of the 30 separate problem
items (P<.05). Unchanged items included problems regarding phantom limb pain and
pain from the back, shoulders, and contralateral limb. The PF, PCS, and SF-6D
improved a mean of 24.1 +/- 21.4 (P<.0001), 8.5 +/- 9.7 (P<.0001), and .039 +/-
.11 (P=.007) points, respectively. Walking energy cost decreased (mean PCI at
baseline, .749; mean PCI at follow-up, .61; P<.0001). CONCLUSIONS: Two years
after intervention, patients with a unilateral TFA treated with an OPRA implant
showed important improvements in prosthetic function and physical quality of
life. However, walking aids used and the presence of phantom limb pain and pain
in other extremities were unchanged. This information is valuable when
considering whether percutaneous osseointegrated prostheses are a relevant
treatment option.
CI - Copyright (c) 2014 American Congress of Rehabilitation Medicine. Published by
Elsevier Inc. All rights reserved.

Langue : ANGLAIS